Medical Condition News

RSS

New therapeutic treatment may provide a potential alternative to bone grafting operation

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

Interim results from Phase I clinical trials utilizing PLX-PAD for treatment of CLI reported

Pluristem Therapeutics Inc. today announced interim results from their Phase I clinical trials utilizing their placenta derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

12 Jan 2010

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in the Phase 1 clinical study of BMN 195, a small molecule utrophin upregulator, for the treatment of Duchenne muscular dystrohpy (DMD). Initial top-line results are expected in the third quarter of 2010.

12 Jan 2010

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allergy immunotherapy, generally referred to as allergy vaccinations or shots, reduce total health care costs in children with allergic rhinitis (hay fever) by one-third, and prescription costs by 16 percent, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

11 Jan 2010

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF).

11 Jan 2010

Targacept signs collaboration and license agreement with AstraZeneca

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

11 Jan 2010

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).

11 Jan 2010

NIH renews grant to continue cell growth regulation research

The new year began on a high note for Alan Leonard and Julia Grimwade, professors of biological sciences at Florida Institute of Technology, when they learned their National Institutes of Health grant, which they have held for the last 11 years, had been renewed for four more years. The competitive renewal brings them $1,024, 944 to continue their research into the regulation of cell growth and division.

11 Jan 2010

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

Raptor Pharmaceutical Corp. ("Raptor" or the "Company"), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

11 Jan 2010

New technique may help researchers to test amyloid hypothesis in AD development

Current Alzheimer's disease (AD) research indicates that accumulation of amyloid-beta (Aβ) protein plaques in the brain is central to the development of AD.

11 Jan 2010

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics announced today that the Company received a $5 million award from the State of Texas through the Texas Emerging Technology Fund (“ETF”). The ETF was created with the goal of growing new and existing businesses to accelerate the introduction of new products and services in the marketplace. This is the largest award of this type that has ever been granted.

11 Jan 2010

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Meda has in-licensed exclusive rights to Ceplene (histamine dihydrochloride) from EpiCept Corporation, a US-based biopharmaceutical company.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Ask anyone who suffers from migraine headaches what they do when they're having an attack, and you're likely to hear "go into a dark room." And although it's long been known that light makes migraines worse, the reason why has been unclear.

11 Jan 2010

Common brain tumour in children can arise from stem cells

New research from scientists at Queen Mary, University of London shows how the most common type of children's brain cancer can arise from stem cells.

11 Jan 2010

Autism spectrum disorders result from miswiring of connections in developing brain

Studying a rare disorder known as tuberous sclerosis complex (TSC), researchers at Children's Hospital Boston add to a growing body of evidence suggesting that autism spectrum disorders, which affect 25 to 50 percent of TSC patients, result from a miswiring of connections in the developing brain, leading to improper information flow.

10 Jan 2010

Research into "chemical chaperone" may lead to new treatments for heart attacks

Researchers at the Indiana University and Stanford University schools of medicine have determined how a "chemical chaperone" does its job in the body, which could lead to a new class of drugs to help reduce the muscle damage caused by heart attacks.

10 Jan 2010

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

New book on baking recipes for people with food allergies

More than 12 million Americans suffer from food allergies, or one in 25. According to The Food Allergy & Anaphylaxis Network, one in 17 children age three and under have a food allergy, and these numbers are rising rapidly. The rate of peanut allergy alone has doubled over the last ten years.

9 Jan 2010

Phonak's "Hear the World Tour" exhibit to raise hearing loss awareness at Miami

The Hear the World initiative by Phonak will bring the Hear the World Tour - a traveling photography exhibit - to Macy's at Dadeland Mall (Miami, FL) to raise awareness about hearing loss, a growing issue that affects 31 million Americans. After officially joining forces in October 2009, Phonak and Macy's kicked-off a cross-country hearing awareness tour that debuted in Dallas and San Francisco in the fall.

9 Jan 2010

Medical Condition News

New therapeutic treatment may provide a potential alternative to bone grafting operation

Interim results from Phase I clinical trials utilizing PLX-PAD for treatment of CLI reported

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Targacept signs collaboration and license agreement with AstraZeneca

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

NIH renews grant to continue cell growth regulation research

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

New technique may help researchers to test amyloid hypothesis in AD development

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Common brain tumour in children can arise from stem cells

Autism spectrum disorders result from miswiring of connections in developing brain

Research into "chemical chaperone" may lead to new treatments for heart attacks

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

New book on baking recipes for people with food allergies

Phonak's "Hear the World Tour" exhibit to raise hearing loss awareness at Miami

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Latest News